CIK 0001826457
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Monte Rosa Therapeutics, Inc.
Sign in to watch- Ticker
- GLUE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 617-949-2643
- Business address
- 321 HARRISON AVENUE, SUITE 900, BOSTON, MA, 02118
- Former names
- Monte Rosa Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $137
- in 1 filing
Net −$137. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-04-09 | Nickson Philip Chief Business & Legal Officer | Sale | −5,845 | $17.69 | $103K | 55,000 |
| 2026-01-05 | Nickson Philip Chief Business & Legal Officer | Sale | −3,155 | $15.17 | $48K | 60,845 |
| 2026-01-02 | Nickson Philip Chief Business & Legal Officer | Grant or award | +28,000 | 64,000 | ||
| 2026-01-02 | Nickson Philip Chief Business & Legal Officer | Grant or award · Stock Option (Right to Buy) | +126,000 | 126,000 | ||
| 2025-01-02 | Nickson Philip Chief Business & Legal Officer | Grant or award | +36,000 | 36,000 | ||
| 2025-01-02 | Nickson Philip Chief Business & Legal Officer | Grant or award · Stock Option (Right to Buy) | +161,000 | 161,000 | ||
| 2024-06-03 | Nickson Philip Chief Business & Legal Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2024-01-02 | Nickson Philip General Counsel | Grant or award · Stock Option (Right to Buy) | +109,000 | 109,000 | ||
| 2023-01-03 | Nickson Philip General Counsel | Grant or award · Stock Option (Right to Buy) | +123,650 | 123,650 | ||
| 2022-03-01 | Nickson Philip General Counsel | Grant or award · Stock Option (Right to Buy) | +70,600 | 70,600 |
Page 1 of 1 · 10 trades